Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 11:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 841–864 of 2,287 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fasted State Clear all

Conditions: Blood Glucose Monitoring
Interventions: YES Bar; Other
Lead sponsor: Efforia, Inc; Industry
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis
Interventions: VNZ/TEZ/D-IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Lansoprazole, Prevacid®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Nutritional Status
Interventions: GSK1325756; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes
Interventions: 3 day fast, 3 day CHO-free diet; Other
Lead sponsor: Minneapolis Veterans Affairs Medical Center; Federal
Eligibility: 45 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Lotensin HCT® Tablets 20 mg/25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Thermal Burn
Interventions: Celution Device; Device
Lead sponsor: Cytori Therapeutics; Industry
Eligibility: Up to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Phoenix, Arizona • San Diego, California • Galveston, Texas + 1 more

Conditions: Gestational Diabetes
Interventions: Mobile health app called "Hola Bebe"; Behavioral
Lead sponsor: Environment and Health Group, Inc.; Industry
Eligibility: 19 Years to 45 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Insulin aspart, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 50 Years to 89 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Diet Modification, HDL, Inflammation
Interventions: Mediterranean Diet, Fast food diet; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 19 Years to 30 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Davis, California

Conditions: Mild Cognitive Impairment
Interventions: PEP, CCI; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 60 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Muscle Soreness
Interventions: Cannabidiol cream, Placebo cream; Other
Lead sponsor: Joseph Pastina; Other
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lexington, Kentucky

Conditions: Shigellosis
Interventions: Shigella sonnei 53G, Shigella flexneri 2a 2457T; Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 50 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity, Childhood Obesity, Hypertension, Diabetes, Dyslipidemia
Interventions: Families on Track Intervention; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Durham, NC, North Carolina

Conditions: Hepatic Impairment, Healthy Participants
Interventions: Opevesostat, Prednisone, Fludrocortisone acetate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Miami, Florida • San Antonio, Texas

Conditions: Cocaine Dependence
Interventions: Doxazosin, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spatial Neglect, Stroke
Interventions: Prism adaptation therapy (PAT) + Electrical stimulation (E-stim), Prism adaptation therapy (PAT) + Sham Stimulator, Gait Training; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Nisoldipine Extended-release Tablets, 30 mg, Sular® Extended Release Tablets, 30 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Clinical Pharmacology
Interventions: Naproxen sodium and diphenhydramine hydrochloride soft capsules, Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity
Interventions: REMD-477, Placebo Subcutaneous injection; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Cognitive Dysfunction, Schizophrenia
Interventions: KYN-5356, placebo; Drug
Lead sponsor: Kynexis B.V.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: Fasting; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 21 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Fasting
Interventions: r-metHuLeptin, placebo; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Zonisamide, Zonegran; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Fort Myers, Florida

Search by objective public record fields.

How Does YES Bar Affect Blood Glucose Levels?

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Lansoprazole 30 mg DR Capsule Replicate Food Study

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

Metabolic Response to 3-day Fast Versus Carbohydrate-free Diet in Type 2 Diabetes

Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg

Feasibility of Obtaining ADRCs From Discarded Thermal Burn Eschar Tissue Using Investigational Celution® System

Mobile Health App to Reduce Diabetes in Latina Women

Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart

Effects of Short-term Diet on HDL Composition and Function

Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment

Topical CBD's Effects on Soreness and Performance

Controlled Human Infection Model Challenge/Rechallenge

Families on Track: A Digital Health Behavioral Intervention for Parents Seeking Treatment for Their Child With Obesity

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

The Efficacy of Doxazosin for Cocaine Users

Spatial-Motor Stroke-Rehab Study

Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions

Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years

The Effect of Calorie Deprivation on Adipose Tissue Distribution

Role of Leptin in the Neuroendocrine and Immune Response to Fasting

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions